Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 5, 2013
Grant Date -
N/A
app pub date -
Jul 9, 2010
filing date -
Jul 14, 2009
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Ischemia-reperfusion (IR) injury involving harvested organs and allograft transplantation may be increased by stimulation of a newly described innate pro-inflammatory immune system (i.e.NALP-3-inflammasome) which can cause secretion of IL-1β and subsequent neutrophilic inflammation. Ischemia and hypoxia can cause metabolic acidosis and development of danger signals known to stimulate IL-1β secretion from the NALP-3 inflammasome. Based on this newly discovered mechanism causing pathobiology in IRI, IL-1β targeted therapy would be capable of improving allograft tolerance, viability of harvested organs and in conditions with compromised arterial blood supply and subsequent reperfusion, such as replants, compartment syndrome, and serious vascular accidents.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully